Dry Powder Formulation: Outlining The Trends And Challenges In The Inhaled Drug Delivery Market

By Richard Johnson, Founder of Upperton Pharma Solutions

The global rise in respiratory diseases, along with the growing interest in systemic drug delivery, is transforming the landscape of inhaled drug delivery. Traditional pressurized metered dose inhalers (pMDIs) are being increasingly supplemented, and in some cases replaced, by dry powder inhaler (DPI) formulations. DPIs offer a promising alternative, aligning with evolving market trends and the demand for next-generation inhaled therapeutics. These formulations provide several advantages, including improved patient compliance and the potential for enhanced drug stability and delivery precision.

In this article, Richard Johnson, Founder of Upperton Pharma Solutions, delves into the key trends shaping the inhaled drug delivery market, with a particular emphasis on the role of DPIs. He also addresses the challenges associated with dry powder formulation, offering insights on how these obstacles can be overcome to ensure effective therapeutic delivery. As the market continues to evolve, DPIs stand at the forefront of innovation in inhaled drug therapies.